Wird geladen...
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
Aprepitant, a selective high-affinity antagonist of human substance P/neurokinin 1 (NK(1)) receptors, is the active ingredient of EMEND(®) which has recently been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant undergoes extensive metabolism, pri...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2007
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2673828/ https://ncbi.nlm.nih.gov/pubmed/17722507 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|